If all of the above remain unsuccessful, then the last resort is systemic anti-angiogenic agents such as intravenous (IV) bevacizumab, which works by primarily targeting vascular endothelial growth factor (VEGF), reducing the formation of new blood vessels, reducing the incidence of anemia, epistaxis, and high output cardiac failure. This evidence concerns the gene VEGFA and anemia.